Search company, investor...


Founded Year



Acquired | Acquired

Total Raised




About Hemosphere

Hemosphere is an early stage medical device developer of a vascular access technology for hemodialysis.

Headquarters Location

6545 City West Parkway

Eden Prairie, Minnesota, 55344,

United States


Missing: Hemosphere's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Hemosphere's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Hemosphere Patents

Hemosphere has filed 5 patents.

patents chart

Application Date

Grant Date


Related Topics




Nephrology, Kidney diseases, Vascular surgery, Implants (medicine), Membrane technology


Application Date


Grant Date



Related Topics

Nephrology, Kidney diseases, Vascular surgery, Implants (medicine), Membrane technology



Latest Hemosphere News

Edwards Lifesciences : Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff

Jun 1, 2021

06/01/2021 | 04:16pm EDT Message : *Required fields IRVINE, Calif., June 1, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced that Acumen Hypotension Prediction Index (HPI) software with the Acumen IQ finger cuff has received U.S. Food and Drug Administration clearance. This is the first noninvasive solution that unlocks Acumen HPI software and uses machine learning to alert clinicians of the likelihood a patient is trending toward hypotension, or low blood pressure. Until now, Acumen HPI software has only been available for patients using an invasive arterial line. "Numerous studies, including our research, have demonstrated an association between intraoperative hypotension and increased risk of acute kidney injury, myocardial injury and even death," said Kamal Maheshwari, M.D., MPH, anesthesiologist from Cleveland Clinic Foundation. "The noninvasive Acumen IQ cuff provides the opportunity to reduce hypotension in a broader range of patients, including those who do not require an invasive arterial line. The cuff, along with the predictive capabilities of Acumen HPI software to proactively manage hypotension, will have a meaningful impact on patients." In addition to unlocking predictive capabilities, Acumen IQ cuff provides access to automatically calculated, beat-to-beat hemodynamic parameters including mean arterial pressure and cardiac output. It will be available on the HemoSphere advanced monitoring system in the coming weeks. "This latest predictive technology demonstrates our commitment to patient care and providing clinicians with 'smart' monitoring tools that allow for better prediction and management," said Katie Szyman, Edwards' corporate vice president, critical care. "We are extremely optimistic about launching Acumen IQ cuff and providing a tool to help clinicians make informed decisions for their patients, with the goals of reducing complications and helping patients with a quicker return to their families and their daily lives." About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube. This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, statements by Dr. Maheshwari and Ms. Szyman and expectations regarding the potential benefits of HemoSphere, Acumen Hypotenstion Prediction Index, Acumen IQ and future products. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors, including but not limited to, unanticipated outcomes of longer term clinical experience with the products, or unanticipated manufacturing, quality, or regulatory developments. These and other additional factors are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2020 and its subsequent quarterly reports on Form 10-Q. These filings, along with important safety information about our products, may be found at . Edwards, Edwards Lifesciences, the stylized E logo, Acumen, Acumen IQ, HemoSphere, and HPI, are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. View original content to download multimedia: SOURCE Edwards Lifesciences Corporation

Hemosphere Frequently Asked Questions (FAQ)

  • When was Hemosphere founded?

    Hemosphere was founded in 1998.

  • Where is Hemosphere's headquarters?

    Hemosphere's headquarters is located at 6545 City West Parkway, Eden Prairie.

  • What is Hemosphere's latest funding round?

    Hemosphere's latest funding round is Acquired.

  • How much did Hemosphere raise?

    Hemosphere raised a total of $25.3M.

  • Who are the investors of Hemosphere?

    Investors of Hemosphere include CryoLife, Sapient Capital, Cutlass Capital, Affinity Capital Management, Ascension Ventures and 6 more.

  • Who are Hemosphere's competitors?

    Competitors of Hemosphere include MedShape, Respicardia, Access Scientific, Neotract, Vascular Pathways and 12 more.

Compare Hemosphere to Competitors


GRAFTcath is a medical device company developing vascular access products for hemodialysis.

Claros Diagnostics

Claros Diagnostics is an early stage device company developing a POC multiplex diagnostic focused on a biomarker panel for prostate cancer.

Hemosphere (formerly GRAFTcath)

Hemosphere (formerly GRAFTcath) has developed a vascular access product that has the potential to reduce the risk of bacteremia, or severe infection, posed to catheter-dependent patients undergoing hemodialysis.

Primaeva Medical

Primaeva Medical is an early stage medical device company developing a skin tightening and rejuvenation dermatological device

ExploraMed V

ExploraMed is a medical technology incubation company dedicated to the identification, creation and development of medical device solutions. ExploraMed creates ideas in the fields of clinical, engineering, legal, strategic marketing, and financing, while focusing on efficient and timely development.

Vascular Closure Systems

a medical device company, based in part on intellectual property of CardioVascular Technologies, Inc. (, and is focused on the development and commercialization of the vascular access closure technology for the Interventional Cardiology market. The company is comprised of several seasoned medical device professionals and physicians, with a proven record of innovation, clinical acumen, access to the industry and successful commercialization of multiple medical device technologies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.